Gilli, StefanieStefanieGilliNovak, UrbanUrbanNovakMansouri Taleghani, BehrouzBehrouzMansouri TaleghaniBaerlocher, Gabriela M.Gabriela M.BaerlocherLeibundgut, KurtKurtLeibundgutBanz Wälti, Yara SarahYara SarahBanz Wälti0000-0003-4474-3132Zander, ThiloThiloZanderBetticher, DanielDanielBetticherEgger, ThomasThomasEggerRauch, DanielDanielRauchPabst, Thomas NiklausThomas NiklausPabst2024-12-132024-12-132017https://boris-portal.unibe.ch/handle/20.500.12422/192871BEAM with BCNU is commonly used for conditioning treatment followed by autologous stem cell transplantation (ASCT). However, pulmonary toxicity and availability issues associated with BCNU prompted us to evaluate bendamustine-replacing BCNU (BeEAM). We analyzed 39 lymphoma patients receiving BeEAM conditioning with 200 mg/m(2) bendamustine at days -7 and -6. The median duration until neutrophil recovery was 11 days, and 15 days for platelet recovery (>20 g/L). The most common grade 3/4 non-hematologic toxicities comprised mucosal side effects (27 pts.). Pulmonary toxicity was observed in one patient (2.5%), and one patient died of septic complications. The CR rate increased from 33% to 74% 100 days after ASCT. After a median follow-up of 18.5 months, progression and death each occurred in 11 patients (28%). Median progression-free and overall survival at 2 years were 69% and 72%. Our data suggest that BeEAM conditioning using bendamustine is safe and results in promising survival rates.enAutologousBCNUBeEAMBeamBendamustineChemotherapyHigh doseLymphomaPrognosisStem cellSurvivalTransplantation / Baerlocher Gabriela M. / Mansouri Taleghani Behrouz600 - Technology::610 - Medicine & health500 - Science::570 - Life sciences; biologyarticle10.7892/boris.936892801198510.1007/s00277-016-2900-y